IndustryCompany release

Azenta licenses Elegen's cell-free DNA platform and acquires SynPlexity to grow GENEWIZ gene synthesis

🇺🇸 Azenta, Inc. (AZTA) · Fri 30 Oct 2026

The US life-sciences services group has signed an exclusive licence and made an acquisition to widen GENEWIZ's gene synthesis offering for antibody discovery, protein engineering and AI-enabled drug discovery.

Azenta, Inc. announced on 30 October 2026 that it has signed an exclusive licence with Elegen Corp. for a cell-free DNA synthesis platform. On the same day it said it had acquired SynPlexity Inc., a maker of pooled high-throughput gene libraries.

Together, the two moves are intended to extend the gene synthesis offering of GENEWIZ, Azenta's genomics services business. The company points to antibody discovery, protein engineering and AI-enabled drug discovery as the target uses.

The source material available to VigiEye does not give financial terms, the licence's duration or scope, or a timetable for integrating the technology and the acquired business. No regulator is involved in the transactions.

Azenta has said further details will be provided on its fiscal fourth-quarter 2026 earnings call.

What it means for your team

  • No regulatory action is attached to the deal, so there are no direct filing or compliance consequences for sponsors at this stage.
  • Teams that source synthetic genes or variant libraries from GENEWIZ should watch for service, lead-time or specification changes once the new capabilities are integrated.
  • Financial terms and integration plans are still undisclosed; the fiscal fourth-quarter 2026 earnings call is the next expected source of detail.

Company's press release (SEC filing): Azenta, Inc. ↗

Article written by VigiEye from the official source (Azenta, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →